ACE-031 vs Follistatin-344.

ACE-031 (ramatercept) is not a peptide but a recombinant fusion protein that joins the extracellular domain of the human activin receptor type IIB (ActRIIB) to the Fc region of IgG1. Developed by Acceleron Pharma, it works as a ligand trap that soaks up myostatin and related TGF-beta-family proteins that normally restrain muscle growth. It was engineered as a candidate therapy for muscle-wasting conditions, most prominently Duchenne muscular dystrophy (DMD). Unlike most compounds grouped with muscle peptides, it genuinely reached human clinical trials before its development was stopped.

Follistatin-344 (FS-344) is an alternatively spliced isoform of human follistatin, a naturally occurring secreted glycoprotein that acts as a high-affinity antagonist of several TGF-beta superfamily ligands. The "344" refers to a 344-amino-acid precursor variant; relative to the longer FS-315 serum isoform, it lacks the C-terminal acidic tail and was selected for therapeutic use partly to reduce off-target heparin/cell-surface binding. In gene-therapy programs it is the FS344 transgene that is delivered, not an injected peptide product, although it is now marketed in gray-market channels as a "research peptide."

ActRIIB is a receptor through which myostatin (GDF-8), activins, and several other TGF-beta-superfamily ligands signal to limit skeletal muscle mass. By presenting a soluble decoy receptor, ACE-031 binds these ligands in the circulation and prevents them from activating ActRIIB on muscle, releasing the brake on muscle growth. Because the trap captures multiple ligands beyond myostatin, including some that act on blood vessels, it produces effects outside muscle as well. This mechanism was established in animal models and then probed directly in humans.

Follistatin works by binding and neutralizing myostatin (GDF-8) and related ligands such as activin A, GDF-11, and several BMPs, preventing them from engaging activin type II receptors. Because myostatin is a dominant negative regulator of skeletal muscle mass, removing this brake promotes satellite-cell activation, myofiber hypertrophy, and reduced fibrosis. Critically, follistatin neutralizes a broader set of ligands than myostatin-only blockade, which is why follistatin overexpression produces larger muscle gains in animals than myostatin knockout alone. The foundational biology traces to McPherron, Lawler and Lee (Nature, 1997), who showed myostatin loss roughly doubles muscle mass in mice.

ACE-031 has genuine human data. Attie et al. reported a single ascending-dose study in healthy postmenopausal women in Muscle & Nerve (2013, PMID 23169607), observing increases in lean mass and biomarker changes consistent with myostatin inhibition. That was a phase 1 design: a small, single-administration, dose-escalating study in a narrowly selected healthy population, sponsored by the developer Acceleron Pharma, with imaging and biomarker endpoints rather than measures of function, and without the duration needed to detect anything that emerges over months. Campbell et al. published the randomized, placebo-controlled trial in ambulatory boys with DMD in Muscle & Nerve (2017, PMID 27462804), which showed trends toward preserved 6-minute-walk distance, higher lean mass and bone mineral density, and lower fat mass, but was stopped early. Because the trial was terminated before completing enrollment and follow-up, the walking-distance result remained a trend rather than a demonstrated benefit, the study lost the statistical power it had been designed with, and no confirmatory trial was ever run. Every efficacy statement about ACE-031 therefore rests on an interrupted study. This places ACE-031 well beyond the preclinical status of most muscle compounds, even though it never demonstrated confirmed clinical efficacy. The wider myostatin-pathway field has repeated the same pattern. Domagrozumab, an anti-myostatin antibody, failed its primary endpoint in Duchenne muscular dystrophy. Bimagrumab, an ActRII-blocking antibody, has produced consistent increases in lean mass without delivering the functional outcomes originally sought, and its cardiac safety has been examined separately in older adults (PMID 41873146). Increasing muscle mass has proven considerably easier than improving what patients can actually do. For ACE-031 specifically there is no chronic exposure data, no published long-term follow-up of the participants who were treated, no completed outcome trial, and no development activity after the early 2010s from which to draw further evidence.

Human evidence is limited to two small, open-label AAV1-delivered FS344 gene-therapy trials from Nationwide Children's Hospital (Mendell and colleagues), not to any injected-peptide product. A Phase 1/2a trial in Becker muscular dystrophy (6 subjects; Mol Ther 2015, PMID 25322757) reported six-minute-walk gains in some treated patients (e.g., +58 m and +125 m in two subjects) with histological evidence of reduced fibrosis and fiber hypertrophy. A companion sporadic inclusion body myositis trial (6 subjects; Mol Ther 2017, PMID 28279643) reported improved annualized six-minute-walk distance versus untreated controls, though responses were heterogeneous and the comparison used a non-randomized matched control group. These are early-phase, unblinded, very small studies; large-animal support comes from a nonhuman-primate follistatin gene-delivery study (Kota et al., Sci Transl Med 2009, PMID 20368179). No randomized controlled trial, and no trial of FS-344 as a standalone injectable peptide, has demonstrated efficacy. The sIBM functional claims also drew a published methodological critique in Molecular Therapy.

The DMD program was halted in 2011 for safety reasons. Investigators observed dose-related, non-muscle vascular effects, specifically epistaxis (nosebleeds), gum bleeding, and telangiectasias (small dilated skin vessels), attributed to the trap's activity on additional TGF-beta-family ligands. The mechanistic explanation is that a soluble ActRIIB decoy does not bind myostatin alone: it also sequesters activins and bone morphogenetic proteins that help maintain vascular integrity, so the bleeding signal is a predictable consequence of the trap's breadth rather than an idiosyncratic reaction. These events appeared in children being treated for a serious progressive disease, the population most willing to accept risk for benefit, and they were still judged unacceptable. Acceleron and its partner Shire ended the collaboration and did not restart development. Short-term human exposure is documented, but the compound was discontinued precisely because of these off-target vascular signals, and long-term safety was never established. There is no chronic dosing data, no published long-term follow-up of the boys who were exposed, and no immunogenicity or reproductive toxicology in the public record. Later programs targeting the same pathway were deliberately engineered for narrower ligand selectivity in order to avoid this exact problem. Anything sold online under the ACE-031 name is an unapproved recombinant protein produced outside pharmaceutical manufacturing controls, where identity, glycosylation, aggregation state, and endotoxin content are all unverified, and aggregated Fc-fusion proteins carry their own immunogenicity risk. The monitoring a real trial would demand, including vascular and bleeding assessment, dermatologic examination, and anti-drug antibody testing, does not exist outside a clinical setting.

In the two small gene-therapy trials, intramuscular AAV1.FS344 was reported as generally well tolerated over follow-up exceeding two years, but these cohorts are far too small to characterize real risk. Because follistatin broadly inhibits TGF-beta/activin signaling, theoretical and preclinical concerns include effects on reproductive tissues (follistatin was first identified as an inhibitor of FSH secretion), the pituitary-gonadal axis, vascular and cardiac remodeling, and possible influence on tumor biology, none of which are adequately resolved in humans. Gray-market "follistatin-344 peptide" products carry the additional, unquantified hazards of unverified identity, purity, sterility, and the fundamental mismatch that human data come from a delivered gene, not an injected protein. There is no established human safety profile for self-administered FS-344.

ACE-031 was never approved by the FDA or any other regulator, and its clinical development was terminated in the early 2010s after the DMD trial was stopped for safety. It is not a marketed drug and is not legitimately available for human use. Any product sold online as ACE-031 is unapproved research-grade material.

Follistatin-344 is not approved by the FDA (or any major regulator) for any indication; it has only been studied investigationally as an AAV-delivered gene therapy and is sold elsewhere strictly as a research-use-only chemical, not a medicine. Myostatin-pathway inhibition is also of interest to anti-doping bodies, and follistatin/myostatin inhibitors fall under WADA's prohibited categories.